WHO ICTRP trial
A study to test if aleglitazar has a positive effect on the heart of patients…
EUCTR2012-001639-29-GB · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2012-001639-29-GB |
|---|---|
| Public title | A study to test if aleglitazar has a positive effect on the heart of patients with Type 2 diabetes and without cardiac disease, looking at the way the heart processes energy and fat. |
| Scientific title | A single center, double-blind, placebo-controlled, randomized, crossover, phase II study to assess the effect of Aleglitazar on cardiac energetics and function in patients with uncomplicated type 2 diabetes mellitus and no history of coronary artery disease who are drug-naïve or treated with stable… |
| Primary sponsor | F. Hoffmann-La Roche Ltd |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | United Kingdom |
| Conditions | Type 2 diabetes mellitus MedDRA version: 14.1 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and… |
| Interventions | Product Name: Aleglitazar Product Code: RO0728804 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Aleglitazar CAS Number: 475479-34-6 Current Sponsor code: RO0728804 Other descriptive name: dual PPAR alpha/gamma agonist… |
| Registration date | Oct 5, 2012 |
| Secondary IDs | BC25445 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: